Dr. Mary Krause

Mary Krause, Ph.D., is Director of Formulation Development in the Sterile Drug Product Development Department at Bristol Myers Squibb in New Brunswick, NJ. In this role, Mary leads a team of scientists supporting formulation and process development of injectable drug products. She has served as both a drug product development team leader and a CMC team leader for early- to late-stage clinical products in the parenteral space. Her leadership has guided the development of monoclonal antibodies and novel protein-based modalities—including antibody-drug conjugates, bispecific antibodies, and fusion proteins—as well as small molecule injectable products. Mary is passionate about mentoring women in STEM and serves on the global leadership team for the Bristol Myers Squibb Network of Women (B-NOW).

Prior to joining BMS, Mary earned her B.S. and M.S. degrees in Chemistry from Missouri State University and her Ph.D. in Chemistry from the University of Kansas. Her doctoral research, conducted in the lab of Dr. Jennifer (Laurence) Chadwick, in strong partnership with Dr. Tim Jackson, focused on characterizing a novel metal-binding peptide tag and its resulting metal complexes, including platinum-protein conjugates designed for targeted anti-cancer therapeutics. Following her graduate studies, Mary continued this research at the University of Kansas as a PhRMA Foundation Postdoctoral Fellow in Pharmaceutical Chemistry and later as a Scientist at Echogen, Inc.—a startup company that licensed the technology. She is the lead author/co-inventor on numerous patents, publications, conference presentations, and invited lectures.